Upstream Bio Stock (NASDAQ:UPB)

Revenue Financials Chart

Previous Close

$7.77

52W Range

$5.14 - $29.46

50D Avg

$7.75

200D Avg

$14.89

Market Cap

$451.66M

Avg Vol (3M)

$260.47K

Beta

0.49

Div Yield

-

UPB Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

52

IPO Date

-

Website

UPB Performance

UPB Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$2.37M	$2.38M	$1.21M
Operating Income	$-77.76M	$-40.11M	$-23.91M
Net Income	$-62.81M	$-20.54M	$-23.87M
EBITDA	$-77.67M	$-40.05M	$-23.90M
Basic EPS	-	$-1.05	$-0.66
Diluted EPS	-	$-1.05	$-0.66

Fiscal year ends in Dec 24 | Currency in USD